Fycompa: Ph III started

Eisai began the double-blind, placebo-controlled, international Phase III Study 338 to evaluate up to 8 mg/day Fycompa oral suspension for up to 22 weeks in 142 patients ages ≥2 receiving 1-3 concomit...